Literature DB >> 12601677

Inhibitory effects of Oren-Gedoku-To (Huanglian-Jie-Du-Tang) on free radical-induced lysis of human red blood cells.

Nobuyasu Sekiya1, Naotoshi Shibahara, Iwao Sakakibara, Naoko Hattori, Hirozo Goto, Katsutoshi Terasawa.   

Abstract

Oren-gedoku-to (Huanglian-Jie-Du-Tang, OGT) has been used for the treatment of cerebrovascular disease, hypertension, gastritis and liver disease in Japan. The present study was to test our hypothesis that ingestion of Oren-gedoku-to extract (TJ-15) would protect red blood cell (RBC) membrane from free radical-induced oxidation if antioxidants in OGT could be absorbed and circulated in blood. When incubated with RBC suspension, OGT and its four constituting herbs provided strong protection for RBC membrane to hemolysis induced by 2,2-azo-bis (2-amidinopropane) dihydrochloride (AAPH), an azo free radical initiator. The inhibitory effect was in a dose-dependent manner at concentrations of 5 microgram/ml to 500 microgram/ml. Furthermore, the ingestion of 7.5 g of OGT (daily dose) was associated with a significant decrease in susceptibility of RBC to hemolysis in humans. The direct protection of RBC membrane from free-radical attack as observed in the present study could provide an important pathophysiological basis for making use of the favorable hemorheological effect of OGT. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12601677     DOI: 10.1002/ptr.1092

Source DB:  PubMed          Journal:  Phytother Res        ISSN: 0951-418X            Impact factor:   5.878


  2 in total

1.  Fever of unknown origin successfully treated by oren-gedoku-to (huanglian-jie-du-tang).

Authors:  Koichiro Tanaka; Kazuhiko Nara; Tetsuya Nishimura; Keiko Serizawa; Taito Miyazaki; Yoshihisa Urita; Oto Miura
Journal:  Int J Gen Med       Date:  2013-10-07

2.  An Alternative Approach to Atopic Dermatitis: Part I-Case-Series Presentation.

Authors:  Hiromi Kobayashi; Kuniaki Takahashi; Nobuyuki Mizuno; Haruo Kutsuna; Masamitsu Ishii
Journal:  Evid Based Complement Alternat Med       Date:  2004-06-01       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.